Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Total Non-Current Liabilities (2021 - 2025)

Historic Total Non-Current Liabilities for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to $294.0 million.

  • Foghorn Therapeutics' Total Non-Current Liabilities changed N/A to $294.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $294.0 million, marking a year-over-year change of. This contributed to the annual value of $329.5 million for FY2024, which is 925.24% down from last year.
  • Per Foghorn Therapeutics' latest filing, its Total Non-Current Liabilities stood at $294.0 million for Q3 2025.
  • Over the past 5 years, Foghorn Therapeutics' Total Non-Current Liabilities peaked at $422.8 million during Q4 2021, and registered a low of $104.9 million during Q3 2021.
  • Moreover, its 5-year median value for Total Non-Current Liabilities was $379.9 million (2023), whereas its average is $352.3 million.
  • As far as peak fluctuations go, Foghorn Therapeutics' Total Non-Current Liabilities surged by 29036.09% in 2022, and later crashed by 1028.7% in 2023.
  • Foghorn Therapeutics' Total Non-Current Liabilities (Quarter) stood at $422.8 million in 2021, then dropped by 4.26% to $404.7 million in 2022, then dropped by 10.29% to $363.1 million in 2023, then fell by 9.25% to $329.5 million in 2024, then dropped by 10.79% to $294.0 million in 2025.
  • Its Total Non-Current Liabilities was $294.0 million in Q3 2025, compared to $302.1 million in Q2 2025 and $319.5 million in Q1 2025.